Trials involving the drug atorvastatin have been stopped early after results showed that it decreases the risk of myocardial infarction (MI) and stroke in patients with hypertension and low cholesterol levels. Researchers decided to stop the trial as they thought that it would be unfair to those patients receiving placebo.
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) involved 20,000 patients with hypertension and cholesterol levels that were below those recommended for treatment. The trial was designed to compare the effects of newer blood pressure drugs with standard therapies.
Additionally, 50% of the patients were given either atorvastatin 10mg or placebo to measure the effects of lowering cholesterol in people with high blood pressure. There were fewer MI’s and strokes in the group treated with atorvastatin than those in the placebo group.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!